Last reviewed · How we verify
NCT06628206
Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis
Phase 1 trial testing LPX-TI641 in Rheumatoid Arthritis (RA) in 48 participants. Currently enrolling.
15 December 2025
Quick facts
| Lead sponsor | LAPIX Therapeutics Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 15 December 2024 |
| Primary completion | 15 December 2025 |
| Estimated completion | 15 January 2026 |
| Sites | 1 location across Jordan |
Drugs / interventions tested
- LPX-TI641 — full drug profile →
- Placebo
Conditions studied
- Rheumatoid Arthritis (RA) — all drugs for Rheumatoid Arthritis (RA) →
- Psoriatic Arthritis (PsA) — all drugs for Psoriatic Arthritis (PsA) →
Sponsor
LAPIX Therapeutics Inc. — full company profile →
Who can join
18 and older, any sex, with Rheumatoid Arthritis (RA) or Psoriatic Arthritis (PsA). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to study the drug LPX-TI641 in patients with rheumatoid arthritis and psoriatic arthritis. We will compare the safety and tolerability of LPX-TI641 to placebo that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06628206
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of LPX-TI641
Trials testing the same drug.
- NCT06982352 — Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis · Phase 1 · recruiting
- NCT05853835 — First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641 · Phase 1 · completed
Other recruiting trials for Rheumatoid Arthritis (RA)
Currently open trials in the same condition.
- NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
- NCT07438652 — Effect of Mediterranean vs Paleolithic Diet on RA Activity, Sarcopenia and QOL: 12-Week RCT · NA · recruiting
- NCT07264101 — Validity And Reliability Of The Four Square Step Test In Individuals With Rheumatoid Arthritis · recruiting
- NCT07221890 — A Trial of Academic Detailing to Promote Prescribing of Biosimilars · NA · active not recruiting
- NCT07100873 — A Phase 1 Study of ADI-001 in Rheumatoid Arthritis · Phase 1 · recruiting
Other LAPIX Therapeutics Inc. trials
Trials by the same sponsor.
- NCT06982352 — Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis · Phase 1 · recruiting
- NCT05853835 — First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641 · Phase 1 · completed
- NCT05663853 — An Observational Biomarker Study in Multiple Sclerosis (MS) Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06628206 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by LAPIX Therapeutics Inc.
- Last refreshed: 20 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06628206.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing